Roche plots new course for tiragolum­ab as ex­ecs nav­i­gate biosim­i­lar chal­lenges and de­clin­ing Covid-19 sales

Roche’s tiragolum­ab flop ear­li­er this quar­ter set the pro­gram back at least a year, Sev­erin Schwan re­vealed on the com­pa­ny’s Q2 call — but the out­go­ing CEO re­mains hope­ful that the phar­ma gi­ant can “sal­vage a lot of that val­ue.”

Tiragolum­ab racked up a sec­ond straight Phase III fail back in May when it missed the pro­gres­sion-free sur­vival co-pri­ma­ry end­point as a first-line treat­ment com­bined with Tecen­triq for PD-L1-high pa­tients with non-small cell lung can­cer. Schwan said on Thurs­day that he was “per­son­al­ly very dis­ap­point­ed” in the read­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER